Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021.
Tilray products will be administered to qualifying patients in the French experiment, for whom existing treatments do not provide sufficient relief from their symptoms, and for therapeutic indications including:
- Neuropathic pain that is refractory to therapies currently available (drug or non-drug treatments);
- Certain forms of epilepsy that are drug-resistant;
- In certain persistent symptoms in oncology, related to cancer or anti-cancer treatment;
- In palliative care situations;
- In the painful spasticity of multiple sclerosis or other pathologies of the central nervous system.
Tilray has received the necessary regulatory approvals to participate in the ANSM experimentation in France and will export medical cannabis products from its GMP-certified facility in Cantanhede, Portugal.
Brendan Kennedy, Tilray’s Chief Executive Officer, said, “Today's announcement marks another milestone for Tilray as we expand operations in Europe. We are proud to be able to offer access to a variety of high-quality, pharmaceutical-grade medical cannabis products to the ANSM while supporting patients in need in France.”
Sascha Mielcarek, Tilray’s General Manager for Europe, said, “We are pleased to be chosen by the ANSM and fully appreciate the stakes of this experiment for French patients, and we are determined to contribute to its success actively. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being.”
Tilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.
Tilray (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 15 countries spanning five continents.
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading "Risk Factors" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
For further information:
Media, Tilray Global: email@example.com
To request an interview opportunity:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant360 ® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers2.3.2021 14:05:00 CET | Press release
Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR)alterations who may benefit from treatment with Tagrisso® (osimertinib). The Guardant360 CDx test offers patients and clinicians a simple, faster blood test to help inform personalized treatment options. The Guardant360 CDx received U.S. FDA approval in August 2020. “Gaining the CE-mark for our Guardant360 CDx test is an important step to making our test more widely accessible to patients around the world. We are committed to helping cancer patients be comprehensively tested to see if they are appropriate for potentially life-changing personalized treatments,” said Helmy Eltoukhy, Guardant Health CEO. The World Health Organization est
Red Fox ID and Cepton Enable Barrier-Free, High-Speed Tolling Worldwide With High Performance Lidar Based Solutions2.3.2021 14:00:00 CET | Press release
A state-of-the art electronic tolling system that utilizes high-performance lidar sensors from Cepton and a cutting-edge vehicle identification solution from Red Fox ID is expected to be deployed on a major highway turnpike crossing multiple states in the United States, thereby promising fast, highly accurate, barrier-free, real-time tolling to enable smooth traffic flows. This marks the maturing of the deep partnership between Cepton and Red Fox ID in bringing innovative, automated tolling solutions to major customers across North America, EMEA and Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005524/en/ Cepton’s MMT®-powered Sora-P lidars feature an industry-leading 380 Hz frame rate to deliver 1140 line scans per second, providing high-fidelity profiling of vehicles passing at highway speeds. © 2021 Cepton Technologies. Based on an extended collaboration with leading lidar solution provider Cepton, Red Fox ID
ALPINION Launches X-CUBE 90, A High-Performance Ultrasound Diagnostic System2.3.2021 14:00:00 CET | Press release
ALPINION MEDICAL SYSTEMS Co., Ltd (ALPINION), a medical ultrasound professional, announced that it will launch X-CUBE 90 in March. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005348/en/ ALPINION MEDICAL SYSTEMS launches X-CUBE 90, a high-performance ultrasound diagnostic system. X-CUBE 90 provides high-resolution diagnostic images with X+ Architecture. X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. X-CUBE 90 increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products. (Photo: Business Wire) X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. Compared to the existing models, X-CUBE 90 provides a more detailed image and comfortable user interface and thus a diagnostic environment of greater efficiency. X-CUBE 90 appl
Sintavia Acquires Three Additional GE Additive Arcam A2X Electron Beam Printers2.3.2021 13:59:00 CET | Press release
Sintavia, LLC, a designer and 3D printer of a new generation of flight and launch components, announced today that it had acquired three GE Additive Arcam A2X electron beam printers. The new electron beam printers will join the company’s four other electron beam printers, including three GE Additive Arcam Q20plus machines and one other A2X. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005184/en/ (Photo: Business Wire) “We are big believers in the electron beam process for high precision structural components manufactured in titanium,” said Brian Neff, Sintavia’s Chief Executive Officer. “It has been a great pleasure to work with GE Additive to develop successful manufacturing strategies for critical aerostructure components. We are excited to expand our production platform using the electron beam process in the months and years to come.” “It’s great to see continued momentum and innovation at Sintavia. The recent add
Tecnotree Posts Strong Growth in 2020 Despite Pandemic & Global Slowdown2.3.2021 13:56:00 CET | Press release
Tecnotree, the global provider of IT solutions for the telecom industry, has recently announced its Q4 and full-year 2020 financial results. In a year that will globally go down in history as the year of pandemic and resultant economic slowdown, Tecnotree posts a different story. With a substantial 76% increase in net income and 48% EBIT growth, Tecnotree displayed strong resilience even during the most difficult times. The company struck the right chord for all the key metrics in 2020; and with 4 new clients and an Order-Book of more than €32 million, Tecnotree appears set to continue the growth momentum in 2021. 2020 year performance at a glance: Net sales grew by 12% to €52.8M (€47M) Net income registered 76% growth to €13.6M (€7.7M) Earnings Before Interest and Tax (EBIT) grew by 30% to €18.6M (€14.4M) Cash & Cash Equivalent showed a 138% growth at the end of the period Share price soared by 312% in the year Market Capitalization grew by 360% to 193Me (42Me) EPS grew to 5c from 3c
Theramex Launches New Website2.3.2021 13:44:00 CET | Press release
Theramex, a global company specialised in women's health, has launched a new website. It is a modern, intuitive and easy-to-navigate site that seeks to position itself as a benchmark for information on the company's four main working areas: menopause, osteoporosis, fertility, and contraception. "This year we are strongly committed to a process of digital transformation of the company to bring it closer to our audiences: healthcare professionals, patients and users. A key step in our strategy could not be other than renewing our website and bringing it to the forefront", says Robert Stewart, CEO of the company. In the coming weeks, different new features will be implemented, and local websites will also be launched where Theramex has a presence, offering specific content adapted to the needs of each country. In addition, there will be a validated-private section for healthcare professionals where they can access information about our treatments, products and therapeutic novelties. Addin
Jetcraft Announces Partnership With Synerjet; Cementing South American Presence2.3.2021 13:00:00 CET | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is announcing a strategic relationship with Synerjet, a Latin American business aviation specialist, further strengthening the company’s footprint in the Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005544/en/ Todd Spangler, Americas Sales Director at Jetcraft (left), and Fabio Rebello, Chief Commercial Officer at Synerjet (right), mark the start of their strategic relationship. Synerjet, a Latin American business aviation specialist, will operate as an official Jetcraft authorized representative in the South America Region. (Photo: Business Wire) The aircraft sales division of Synerjet will operate as an official Jetcraft authorized representative in the South America region, enabling Jetcraft to increase its offering to its clients looking to buy, sell or trade in, with local support from Synerjet’s experienced executives. Synerjet joins J
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom